MerckVaccines.com

Important Recommendations


	GARDASIL
	Product Features
	Indications
	Efficacy
	Safety and Tolerability
	Dosage and Administration
	Storage and Handling

	Prescribing Information
	Patient Product Information
	Select Safety Information

	Practice Integration
	Important Recommendations
	Reimbursement Information
	Compliance in Your Practice
	Complimentary Resources

	What Your Patients See

	Disease Information

Select Another Product

GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by human papillomavirus (HPV) Types 6, 11, 16, and 18.

Select Safety Information

GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.

GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should continue to undergo screening per standard of care.

GARDASIL is not recommended for use in pregnant women.

Vaccination with GARDASIL may not result in protection in all vaccine recipients.

GARDASIL is not intended to be used for treatment of active genital warts, cervical cancer, cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.

GARDASIL has not been shown to protect against diseases due to non-vaccine HPV types.

The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness. In addition, common postmarketing reports include vomiting and syncope.

GARDASIL should be administered in 3 separate intramuscular injections in the deltoid region of the upper arm or in the higher anterolateral area of the thigh over a 6-month period with the first dose at an elected date, the second dose 2 months after the first dose, and the third dose 6 months after the first dose.

Before administering GARDASIL, please read the Prescribing Information and Patient Product Information.

^a	Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.
^b	American College of Obstetricians and Gynecologists.
^c	American Academy of Pediatrics. Provisional recommendation. A full policy statement from the AAP is forthcoming.
^d	American Academy of Family Physicians.
^e	Society for Adolescent Medicine.
^f	American College Health Association.
^g	Patients with previous HPV infection, abnormal Pap tests, or genital warts can be protected against the vaccine HPV types with which they have not been infected.

GARDASIL is a registered trademark of Merck & Co., Inc.